Navigation Links
TNO and Seventh Wave sign letter of intent on joint preclinical pharmaceutical outsourcing services
Date:11/9/2009

Delft, the Netherlands, November 09, 2009 / b3c newswire /- Today, TNO, a Dutch contract research organization, and Seventh Wave, an American organization for contract research and consultancy, announce that the companies have signed a letter of intent with regard to TNOs dynamic in vitro gastrointestinal models TIM. The letter of intent proposes a collaboration in which Seventh Wave will obtain two TIM systems for commercialization in North America. The TIM systems will be used to determine the behavior of oral drug products and drug substances during passage through the gastrointestinal tract.

According to the terms stated in the letter of intent, TNO will supply its proprietary gastrointestinal models to Seventh Wave Laboratories, located in Chesterfield, Missouri. This central U.S. location, coupled with Seventh Waves customer responsiveness, will shorten study turnaround time for customers in North America. The TIM system has been validated for use in preclinical drug development. Both parties expect the TIM systems to be installed and ready for use by customers in the first quarter of 2010. In addition to the collaboration on the current models, the partners envisage joint projects to further validate the TIM system for new applications.

Niek Snoeij, CEO of TNO Quality of life, explains the benefits of the proposed collaboration as follows: The partnership with Seventh Wave allows us to capitalize on the strengths of the TIM system and offer extra capacity, flexibility, and faster turn-around times.

John Sagartz, President and CEO of Seventh Wave, adds: TIM compliments our current preclinical and clinical services. With the TIM system available on site, we have another valuable tool to solve our customers specific needs in formulation development and pharmacokinetics.

TNO gastroIntestinal Model (TIM)
By simulating accurately the human conditions in the gastrointestinal tract, the TIM system gives insight into the release, solubility, and availability for absorption of pharmaceuticals. This state-of-the-art, validated system has a much higher predictive value than regular dissolution tests. The computer-regulated model can simulate various physiologic states and helps scientists determine the bioaccessibility of active compounds and predict resultant blood concentration after single or repeated intake of various dosage forms.


TNO - http://www.tno.nl/pharma
TNO is an innovative, independent research organization. Through its expertise and the research it conducts, TNO contributes to the quality of work and life in the world. TNO supports and stimulates innovations in companies and organizations, thus improving the competitiveness of the economy. TNOs multidisciplinary approach and ability to apply research give it a unique position. More than 4300 professionals work at TNO.

Seventh Wave - www.7thwavelabs.com

Seventh Wave is a consulting and contract research organization providing integrated preclinical ADME/PK, pharmacology, toxicology, pathology, and clinical PK. With a continuous commitment to quality, Seventh Wave operates its consulting and laboratory services as an extension of its clients project teams in the design and timely execution of their preclinical development strategies.


Contact
(in US)
Albert Stevens
Tel: +31 6 15631194

(in Europe)
Heather Wagner
Tel: +31 306944615

Info-pharma@tno.nl
www.tno.nl/pharma


'/>"/>
b3c newswire

Related biology news :

1. AACR to host Seventh Annual International Conference on Frontiers in Cancer Prevention Research
2. Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network
3. Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network
4. FEBS Letters Structured Digital Abstracts experiment
5. BIO-key(R) Issues Open Letter to Shareholders
6. Explorations Group Announces Letter of Intent to Acquire Specialty Lighting Company
7. Explorations Group Announces Letter of Intent to Acquire Specialty Lighting Company
8. Selected personal letters of Max Perutz are released in new book
9. NEWSLETTER: Antibody Fragment Production Breakthrough with 2nd Generation EBA
10. Taser Notices Intent to Serve Subpoena for Information on Old NIJ Tests in Taser v. Stinger
11. Wii bit of fun at Rice University has serious intent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
(Date:3/22/2016)... and SANDY, Utah , ... which operates the highest sample volume laboratory in ... Genomics and UNIConnect, leaders in clinical sequencing informatics and ... launch of a project to establish the informatics infrastructure ... NSO has been contracted by the Ontario ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
Breaking Biology Technology: